An Alumni of the JLab Houston facility, Stembiosys Inc is structured around maintaining stem cells in a more natural environment during manipulations (isolation and expansion) by which to maintain a more natural phenotype during expansion and prior to selected differentiation. Current methods for stem cell isolation and growth neglect the importance of cell - extracellular matrix interaction and signaling provided by these various substrates. This is the next step in the evolution of cell culture from glass petri dish to tissue culture treated plastics to protein coated substrates to an intact cell derived extracellular matrix. The firms proprietary, novel technology platform is an advanced stem cell culture system - designated HPMEÃ - (High Performance Micro Environment). This system eplicates the niche in which cells naturally reside naturally and where they proliferate. Stembiosys' technology enables users to isolate and grow stem cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and -unlike protein coated dishes - the firm's system represents a natural micro environment produced by cells, for cells. The company's first commercial product - Bone Marrow - is produced using bone marrow stromal cells and has been shown to allow a variety of stem cells to replicate more rapidly and with greater preservation of stem cell phenotype than traditional tissue culture plastic. In January 2020, Stembiosys acquired the biotech startop Cartox - also SBIR-involved - whose principals are involved in developing innovative assays for high throughput screening of human cardiotoxicity.
